According to a press release by Fox, the 9 remaining American Idol hopeful, and that includes MexiPinay Jessica Sanchez will be singing a song from their personal idol come performance night this Wednesday, March 28 and they will be mentored by singer-songwriter and musician Stevie Nicks.

Next week, on Wednesday, March 28 (8:00-10:00 PM ET live/PT tape-delayed), the Top Nine DeAndre Brackensick, Hollie Cavanagh, Colton Dixon, Heejun Han, Skylar Laine, Joshua Ledet, Phillip Phillips, Jessica Sanchez and Elise Testone return to the IDOL stage to sings songs from their own Idols.

Tune in the following night, Thursday, March 29 (8:00-9:00 PM ET live/PT tape-delayed) to the live results show to find out which of the Top Nine finalists is sent home. In addition, Nicki Minaj will take the stage and perform her megahit "Starships" and Season 10 IDOL winner and platinum-selling country artist Scotty McCreery will return to perform his newest single, "Water Tower Town."

Become a fan of AMERICAN IDOL on Facebook at http://www.facebook.com/AmericanIdol. Follow the series on Twitter @AmericanIdol and join the discussion at #Idol. Also, follow host Ryan Seacrest at @RyanSeacrest, and follow the judges: @yo_randyjackson; @JLo; and @iamstevent.

AMERICAN IDOL is produced by 19 Entertainment, a division of CKX, Inc. and FremantleMedia North America, Inc. The series is created and executive-produced by Simon Fuller, CEO, XIX Entertainment, and executive-produced by Cecile Frot-Coutaz, CEO, FremantleMedia North America, Inc.; Ken Warwick, Executive Producer, FremantleMedia North America, Inc.; and Nigel Lythgoe, CEO, Nigel Lythgoe Productions.

The rest is here:
Jessica Sanchez and Other 8 Idol Hopefuls to Sing Personal Idol’s song in Top 9 Performance Night

By Maxwell Fisher - March 26, 2012 | Tickers: HPQ, LXK, XRX | 0 Comments

Maxwell is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited.

Robert Kiyosaki, the author of the Rich Dad, Poor Dad series, got his start with Xerox (NYSE: XRX) back when the company was exploding. The battalion of Xerox salesmen pounding the pavement, knocking down business doors, will draw chuckles and sighs from many a battle-scarred veteran of that particular army. To jog the memory, just as Googling has become English slang today, back then copying a document was called Xeroxing. They were not just a leader, they were THE leader in office document management.

So what happened and where did they go? With such passion and drive from its sales force, it is a mystery that one so far ahead could fall so far behind. I submit that the failure of leadership led to this once great companys decline and paved the way for others such as Hewlett-Packard (NYSE: HPQ) and Lexmark (NYSE: LXK) to dominate the industry.

What Has Happened

Xerox began as a photographic paper company in 1906. It wasnt until 1958 the company changed its name to Xerox and its focus to plain paper copiers, primarily for business use. It has since grown into a global document management corporation that produces and sells an array of printers, photo copiers, and related supplies.

During the early years, Xerox literally had to wait while the market caught up to its vision. The personal computer was almost 20 years away, much less personal printing. To compensate, the company focused on providing businesses with its products and services. This strategy was critical to the companys survival at the beginning, and later became the growth mechanism throughout the 70s and 80s. Unfortunately, leadership became stuck in this focus and stagnated the company due to its inability to see beyond it.

In the mid 70s, Xerox was on the cutting edge of the personal computing industry. In fact, for a hefty $1 million investment, Steve Jobs was able to take a look at its work on the WIMP (Window, Icon, Menu, and Pointing device) system later to be called the mouse. It was his vision that directed the commerciality of the technology by means of the Apple Computer. Jobs is quoted as saying, "They just had no idea what they had."

Sadly, that statement was and has remained prophecy for the late great Xerox.

Read the original post:
Why I Am Bearish On Xerox

Here are three youngsters who have won the district level young scientist competition.

Inquisitiveness, innovation and improvisation in the field of science and technology have led to many astonishing discoveries across the world.

Making a mark

The students, who were chosen for the Young Scientists district level award in Kodagu recently, do not want to make a mark for themselves but also garner glory for the nation.

P. Achutananda, who won the first prize for his project, J. Abraham, who won the second prize, both from St. Anne's High School in Virajpet and M.D. Machaiah, the third prize winner from the Sarvadaivata English Medium School, Aruvatoklu, were thrilled to receive the honour from the elected representatives of the Zilla Panchayat and its officials in Madikeri recently.

The Young Scientist awards were given to the students who involved themselves in creative scientific activities in schools and came up with impressive projects, the secretary of the Kodagu District Vijnana Parishat, T.G. Premkumar, said. The president of the ZP, Ravi Kushalappa, gave away the prizes and cash awards of Rs. 3,000, Rs. 2,000 and Rs. 1,000 to the first three winners respectively. The awards are instituted by the Department of Karnataka Science and Technology. The awardees are now qualify for the State level awards coming up next.

See original here:
Success in the field of Science

Employer:

OpenField Consulting

Updated: Mar262012

Job posting bookmarked!

Overall Job Responsibilities The Business Development Manager builds market position by locating, developing, defining, negotiating, and closing business relationships.In this role, the business will be introduced to new clients in the offshore and Oil and Gas industry.New relationships will be forged with EPC firms and other design firms.With a strong personal network and brand, the Business Development Manager will successfully leverage their industry network into developing profitable business opportunities with new customers.This person will have strong closing skills, motivation for sales, prospecting skills, and sales planning experience.This role has significant job growth and career development opportunity.

Capable of creating and maintaining winning relationships!

Duties and Responsibilities Identify target opportunities before they reach the bid stage by researching industry and related events, publications, and announcements; tracking individual companies and their capital projects plans. Locate or propose potential business opportunities by contacting potential partners; discovering and exploring opportunities. Screen potential business deals by analyzing market strategies, deal requirements, potential, and financials; evaluating options; resolving internal priorities; recommending innovative win strategies such as equity investments. Develop negotiating strategies and positions by studying integration client and company strategies and operations; examining risks and potentials; estimating partners' needs and goals. Close new business deals by coordinating requirements; developing and negotiating contracts; integrating contract requirements with business operations. Protect organization's value by keeping information confidential. Update job knowledge by participating in educational opportunities; reading professional publications; maintaining personal networks; participating in professional organizations. Enhance organization reputation by accepting ownership for accomplishing new and different requests; exploring opportunities to add value to job accomplishments.

Basic Qualifications EDUCATION/LICENSURE: BD Experience- at least 7 years with a demonstrated ability to close large projects. Degree in Engineering, Construction Management or a similar technical field

Preferred Qualifications The ideal candidate will meet basic and preferred qualifications. Preferred qualifications include:

Successfully developed a strong personal brand within the construction / oil and gas / fabrication industry Passion for articulating the Company's value proposition outside of the traditional customer base Demonstrated experience in negotiating and closing construction projects with a value of at least $20 million Ideally performed successfully in a construction project management role. Strong oral and written communications skills Ability to follow work processes, maintain close attention to detail, and meet schedules under deadline Possess solid electronic file management skills and understanding of various electronic data retrieval systems Be able to assist with development of compliance matrix, project descriptions, resumes and schedules Available to travel - 50% Have strong attention to detail and accuracy Ability to work with minimal supervision; self-motivated Superior customer service skills Ability to communicate clearly and concisely Ability to work in a team environment.

View post:
Construction BD Manager

LOS ANGELES, CA--(Marketwire -03/26/12)- MMRGlobal, Inc. (OTC.BB: MMRF.OB - News) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals, today announced that it has filed 186 Provisional Patent Applications covering its health information technology (HIT) portfolio of products and services. The Company's intellectual property portfolio includes biotech assets acquired from its merger with Favrille, Inc. in January 2009 and its portfolio of health IT patents as a result of MyMedicalRecords, Inc.'s patent filings starting in 2005.

MMR's intellectual property includes a comprehensive portfolio of biotech and health information technology patents issued, pending, and applied for. The Company spent more than $140 million in development of the biotech assets which is comprised of patents, patient samples and other IP relating to anti-CD20 antibodies and results from the Company's FavId/Specifid idiotype vaccine trials. The Company offers these assets for license and other strategic partnerships to universities, other biotech companies, institutional investors and others.

The portfolio also includes issued patents on its MyMedicalRecords.com, MyEsafeDepositBox.com and MMRPro document imaging and management systems as well as the pending provisional patents and utility applications in the U.S. and numerous other countries around the world. According to a recent analyst report, the issued patents could be worth in excess of $300 million. The HIT portion of the IP alone has been valued at more than twenty times the Company's market cap, or which could be more than fifty cents per share not including the value of the additional provisional patent filings listed above (http://michaelbass.com/PDF/JAN20MMRF.pdf).

The Company believes that many of the 186 provisional claims could be allowed this year including both health IT and non-health IT/medical applications. These patent claims include 23 claims under 11/690,996, 35 claims under 12/204,474, 30 claims under 12/204,498, 19 claims under 13/352,045, 20 claims under 13/352,068, 15 claims under 13/352,026, and 14 claims under 13/041,809, which address the telecommunications platform, and 18 claims directed toward Electronic Health Records in Clinical Trials under 13/082,896 and 12 claims for Universal Patient Record Conversion Tool under 13/246,948.

During the time of the MMR and Favrille merger, former Favrille management had represented to MMR that its biotech assets were practically worthless; however, after reviewing thousands of files, the Company discovered this was not necessarily the case and began to perfect dozens of biotech patent applications around the world. As a result, the Company has entered into licensing agreements worth at least $13 million, of which the Company continues to receive payments, one as recently as last week, and has recovered patient samples and other assets which it believes are worth many millions more. More recently, as part of the recovery process, the Company discovered thousands of vials of patient samples and other materials at Sanford-Burnham from which the Company identified a significant collection of materials from the Company's biotech IP that includes additional patient samples, samples of the vaccine and other materials. As a result of this find, and just announced, the Company further uncovered a collection of insect cells used in the manufacture of the Company's FavId/Specifid products. These were a particular insect cell that were believed to be susceptible to a particular baculovirus infection providing unique utility including Trichoplusia ni (Hi-5) and Spodoptera Frugiperda (Sf9) cells which are important to the Company and a material element in its issued patents numbers 6,911,204, 8,114,404 and 8,133,486 as well as pending patent applications. This is valuable to MMRGlobal if it is successful with recommencement of research and development into its FavId/Specifid vaccine for treatment of B-Cell lymphomas.

On November 28, 2011, the Company announced it was granted a patent protecting methods of making compositions for B-Cell vaccines and expects to have Notice of Allowance for another U.S. patent protecting "methods of treating a patient with a B-cell lymphoma." The patent covers the methods of making compositions for B-Cell vaccines used in the fight against lymphoma and potentially other forms of cancer.

MMR is focusing on separating its biotech intellectual property from its operating Health IT/PHR business in an effort to maximize the value of the Company's stock for its shareholders. The structure will make it easier to value MMRGlobal in the event of a merger or other transaction given the Company's low share price at this time. MMR, in transaction discussions recently, found that potential acquirers had a difficult time valuing the Company, considering its biotech and HIT patent portfolios. MMR therefore is focusing on further separating its intellectual property from its operating PHR and Health IT businesses to make it easier for other companies in biotech or health IT to make cogent valuation decisions. For example, in a recent transaction, the biotech assets would have been converted to a preferred instrument for the benefit of shareholders of record at closing which the Company believes would not have been in the best interest of shareholders going forward.

According to Robert H. Lorsch, Chairman and Chief Executive Officer of MMRGlobal, "Based on our ability to license our biotech and health IT assets, we believe that the value of our intellectual property is far from accurately reflected in MMRGlobal's current valuation. Potential partners interested in our MyMedicalRecords Personal Health Record and document imaging and management business, and who are interested in investment or other strategic relationships with MMR, find it complicated to deal with the biotech component of our business when valuing a transaction. Separating the two distinct business opportunities allows us to maximize the potential of both."

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId/Specifid vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit http://www.mmrglobal.com. View demos and video tutorials of the Company's products and services at http://www.mmrtheater.com.

View post:
MMRGlobal Announces Filing of Additional 186 HIT Provisional Patent Applications

OXFORD, England--(BUSINESS WIRE)--

NEPHRON+, an EU research project, has recently selected Open Virtual Platforms (OVP) tools for its software and test development environment. Key factors in its decision were ease of use and flexibility of OVP, as well as the availability of ARM processor models chosen for the electronics system.

The NEPHRON+ project is developing a wearable artificial kidney and personal renal care system. According to Frank Poppen of OFFIS - Institute for Information Technology of Germany, the lead institution in the consortium for the embedded software development, OVP was selected because of the ease with which models are built and the flexibility in interfacing to other tools. He continued, The availability of the ARM processor model we needed, and the open source nature of the OVP models, were also important factors.

One of OFFISs development milestones was to interface the OVP simulator, OVPsim, to the Simulink system simulator. This was done to enable testing of the target software, running directly on the processor in the virtual platform, with the full system environment. Due to the open nature of the OVP technology, OFFIS was able to write its own interface model, which is now available on the OFFIS website (http://system-synthesis.org/offissimlink).

OVP is addressing key issues in software development for embedded systems, said Noel Hurley, VP Business Development, ARM. By supporting the creation of virtual platforms, OVP is enabling early software development and helping expand the ARM user community.

OVP processor models are instruction accurate, and very fast. They enable the early creation of software development environments for embedded software developers looking to create hardware-dependent software such as firmware and bare metal applications. OVP processor models employ a state of the art just-in-time code morphing engine to accelerate simulation speeds. Virtual platforms utilizing these OVP processor models can be created with the OVP peripheral and platform models. The processor models can also be integrated into SystemC/TLM2 based virtual platforms using the native TLM2 interface available with all OVP models. The native TLM2 interface enables multiple instantiations of the processor models in a single virtual platform, just as any other component would be instantiated. The OVP simulator can also be encapsulated within the Eclipse IDE, enabling easy use for software developers.

The OVP library of Fast Processor Models includes the complete families of the ARMv4, ARMv5, and ARMv6 architecture-based processors, as well as models of most of the processors in the ARM Cortex-M series and Cortex-A series processors. In addition to working with the OVP simulator, these models work with the Imperas Multiprocessor/Multicore Software Development Kit, M*SDK, which includes advanced tools for multicore software verification, analysis and debug, including key tools for software development on virtual platforms such as OS and CPU-aware tracing, profiling and code analysis.

ARM users recognize the importance of virtual platforms to accelerate the development of software for embedded systems, said Simon Davidmann, Imperas CEO, and OVP founding director. Compatibility and quality of models is essential when using virtual platforms to develop software, and having validated processor models available for free from OVP means developers can get higher quality software developed faster. Validated models really help to close the Software Gap.

Available OVP Fast Processor Models of ARM cores

The following specific models are available as open source from OVP:

See the original post here:
Open Virtual Platforms Selected by NEPHRON+ EU Research Project for Software Development Environment

Research and Markets (http://www.researchandmarkets.com/research/0aabea17/analysis_of_the_pe) has announced the addition of Frost & Sullivan's new report "Analysis of the Personal Care Chemicals Market" to their offering.

This research provides analysis of the personal care chemicals market in Brazil regarding to surfactants, fragrances, emollients, UV filters, propellents, and polymer compounds. The base year is 2011, and the forecast period is 2011 to 2018. The Brazilian personal care industry has an attractive scenario due to fast growth rates. The increasing number of consumers, from an emerging middle class, has expanded the market. Brazil is expected to become the main world supplier of green chemicals ingredients; yet the country is already the third-largest market for personal care products in the world. Brazil is the leading market for deodorants and fragrances, and the second-largest for sunscreen products.

Key Questions This Study Will Answer:

Is the personal care chemicals market growing, how long will it continue to grow, and at what rate?

What are the current and future market trends? Are the existing competitors structured correctly to meet customer needs?

Will these companies and products continue to exist or will they get acquired by other companies? Will the products become features in other markets?

Are the products offered today meeting customer needs, or is additional development needed?

Key Topics Covered:

Market Overview

Total Personal Care Chemicals Market

See original here:
Research and Markets: Analysis of the Personal Care Chemicals Market in Brazil

Video Link: https://www.youtube.com/watch?v=GSPfnDAZkew

26-03-2012 03:36 http://www.englishwithjo.com A student from Hungary shares his experience of learning English online using Skype through the englishwithjo website. He talks about the advantages of online learning and explains what an online English lesson is like.

Read more from the original source:
My Experience of Learning English Online with Jo - Video

Video Link: https://www.youtube.com/watch?v=HNnN4gX4A1o

26-03-2012 07:57 The use of digital media to provide immersion, involvement, presence, copresence in online education presented at MAWCA 2012, Mid-Atlantic Writing Centers Association.

See more here:
Digital Media: Immersion, Involvement, Presence, Copresence in Online Education - Video

Video Link: https://www.youtube.com/watch?v=7vNJEG4eWB8

26-03-2012 14:20 In order for adult learners to meet their educational and related life goals, they need to stick with their online courses. And often they don't. This workshop, aiming to improve adult learner persistence, will be linked to research of techniques and tools used to support persistence in an online ESOL course for adults. Drawing from research in "Making It Worth the Stay: Findings from the New England Adult Learner Persistence Project" (The New England Literacy Resource Center, 2009), you will discover new ways to motivate the learners you work with to stick to it! Learn more at sloanconsortium.org

Go here to see the original:
Intro To Stick With It: Identifying and Overcoming Obstacles to Adult Learner Persistence - Video